Quality of life assessment in esophagectomy patients

Alghamedi, Alla; Buduhan, Gordon; Tan, Lawrence; Srinathan, Sadeesh; Sulman, Joanne; Darling, Gail; Kidane, Biniam

doi:10.21037/atm.2017.11.38

Cited by 26 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are no biomarkers to predict the onset of these forms of endocrine disorders, so regular screening for early detection is mandatory ( 10 ). An in-depth screening for risk factors of autoimmune dysfunction, including personal or familial autoimmune illness like vitiligo, arthritis or autoimmune endocrinopathies may help in the rational selection of patients for this treatment.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Mengíbar

Capel

Bonfill³

et al. 2019

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

Summary Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is associated with increased immune-related adverse events. We report a case of a 55-year-old man who presented to our emergency room with hyperglycaemia after receiving durvalumab for urothelial high-grade non-muscle-invasive bladder cancer. On presentation, he had polyuria, polyphagia, nausea and vomiting, and laboratory test revealed diabetic ketoacidosis (DKA). Other than durvalumab, no precipitating factors were identified. Pre-durvalumab blood glucose was normal. The patient responded to treatment with intravenous fluids, insulin and electrolyte replacement. Simultaneously, he presented a thyroid hormone pattern that evolved in 10 weeks from subclinical hyperthyroidism (initially attributed to iodinated contrast used in a previous computerised tomography) to overt hyperthyroidism and then to severe primary hypothyroidism (TSH: 34.40 µU/mL, free thyroxine (FT4): <0.23 ng/dL and free tri-iodothyronine (FT3): 0.57 pg/mL). Replacement therapy with levothyroxine was initiated. Finally, he was tested positive for anti-glutamic acid decarboxylase (GAD65), anti-thyroglobulin (Tg) and antithyroid peroxidase (TPO) antibodies (Abs) and diagnosed with type 1 diabetes mellitus (DM) and silent thyroiditis caused by durvalumab. When durvalumab was stopped, he maintained the treatment of multiple daily insulin doses and levothyroxine. Clinicians need to be alerted about the development of endocrinopathies, such as DM, DKA and primary hypothyroidism in the patients receiving durvalumab. Learning points: Patients treated with anti-PD-L1 should be screened for the most common immune-related adverse events (irAEs). Glucose levels and thyroid function should be monitored before and during the treatment. Durvalumab is mainly associated with thyroid and endocrine pancreas dysfunction. In the patients with significant autoimmune background, risk–benefit balance of antineoplastic immunotherapy should be accurately assessed.

show abstract

Section: Discussionmentioning

confidence: 99%

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Mengíbar

Capel

Bonfill³

et al. 2019

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

show abstract

“…A avaliação da QVRS em pacientes com câncer de esôfago submetidos à terapia por esofagectomia tem o intuito de ajudar os médicos a entender o impacto da cirurgia e os vários tratamentos e pode ser um complemento importante na tomada de decisão compartilhada, orientação e planejamento do tratamento (ALGHAMEDI et al, 2018).…”

Section: Resultsunclassified

“…Um estudo relatou que pacientes com câncer de esôfago e que também eram acometidos por comorbidades, como por exemplo, distúrbios cardiovasculares, renais, respiratórios, hepáticos, bem como por diabetes, apresentam pior qualidade de vida relacionada à saúde, durante o pós-operatório da esofagectomia (ALGHAMEDI et al, 2018).…”

Section: Resultsunclassified

Qualidade de vida em pessoas acometidas por câncer de esôfago: uma Revisão de literatura/ Quality of life in people with esophageal cancer: a literature review

Silva¹,

Oliveira²,

Pinto³

et al. 2021

Braz. J. Hea. Rev.

View full text Add to dashboard Cite

“…Esophagectomy for cancer strongly impairs postoperative health-related quality of life (HRQL) [1,2]. A systematic review showed that patients undergoing esophagectomy for cancer had scores of physical function, vitality, and performance of health in general significantly lower than those obtained from the reference population [3].…”

Section: Introductionmentioning

confidence: 99%

QOLEC2: a randomized controlled trial on nutritional and respiratory counseling after esophagectomy for cancer

Pinto

Nardi

Marchi

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Background Esophagectomy for cancer strongly impairs quality of life. The aim of this trial was to evaluate the effect of the nutritional and respiratory counseling on postoperative quality of life. Methods At hospital discharge, patients were randomized into four groups receiving respectively: nutritional and respiratory counseling, nutritional counseling alone, respiratory counseling alone, or standard care. The main endpoint was the impairment in quality of life in the first month after surgery. Linear mixed effect models were estimated to assess mean score differences (MDs) in quality of life scores. Results Patients receiving nutritional counseling reported less appetite loss (MD − 17.7, 95% CI − 32.2 to −3.3) than those not receiving nutritional counseling at 1 month after surgery. Dyspnea was similar between patients receiving vs. those not receiving respiratory counseling (MD − 3.1, 95% CI − 10.8 to 4.6). Global quality of life was clinically similar between patients receiving vs. those not receiving nutritional counseling over time (MD 0.9, 95% CI − 5.5 to 7.3), as well as in patients receiving vs. those not receiving respiratory counseling over time (MD 0.7, 95% CI − 5.9 to 7.2). Conclusions Intensive postoperative care does not affect global quality of life even if nutritional counseling reduced appetite loss.

show abstract

Quality of life assessment in esophagectomy patients

Cited by 26 publications

References 42 publications

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Qualidade de vida em pessoas acometidas por câncer de esôfago: uma Revisão de literatura/ Quality of life in people with esophageal cancer: a literature review

QOLEC2: a randomized controlled trial on nutritional and respiratory counseling after esophagectomy for cancer

Contact Info

Product

Resources

About